Ilaria DEL GIUDICE

Sapienza University of Rome

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Luca Laurenti

Università Cattolica del Sacro Cuore

ITALY

View details

Marta COSCIA

Assistant Professor of Hematology

University of Turin

ITALY

View details

Stefano Molica

UNITED KINGDOM

View details

PAOLO SPORTOLETTI

Università degli Studi di Napoli Federico II

ITALY

View details

Giulia Ciotti

Istituto Oncologico Veneto

ITALY

View details

Roberto Marasca

Professore Associato

University of Modena and Reggio Emilia

ITALY

View details

Donato Mannina

Head of Hematology Division

Azienda Ospedale Università Padova

ITALY

View details

Agostino Chiaravalloti

UNIVERSITY TOR VERGATA

ITALY

View details

Gianluca GAIDANO

Professor of Hematology

ITALY

View details

Riccardo Moia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ilaria DEL GIUDICE

Research Interests

Explore related searches

Contact this professor

Articles (10)

Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Does MRD have a role in the management of iNHL ?

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Collaborators (10)

Luca Laurenti

Marta COSCIA

Stefano Molica

PAOLO SPORTOLETTI

Giulia Ciotti

Roberto Marasca

Donato Mannina

Agostino Chiaravalloti

Gianluca GAIDANO

Riccardo Moia

Make your next move.